Fig. 2From: Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practiceEvolution of the mean EORTC QLQ-C30 scores for fatigue, nausea, pain, dyspnea and sleep disturbance (A); and appetite loss, constipation, diarrhea and financial impact (B) throughout the treatment periodBack to article page